Supplement A. Derivation of model equations General scheme of the polymerization and oligomerization processes
To simplify the description of the model we divided derivation of equations into parts: equations for aggregation, equations for oligomerization and finally equations for the complete model including processes of degradation and transport.
Detailed kinetic scheme for the processes of oligomerization, polymerization of amyloid molecules and destruction of amyloid fibrils is given on the figure S1.
Equations for polymerization process in general
Plaque formation occurs due to chain reaction of polymerization, and usually is preceded by the formation of nuclei 1 2 3 . In our model we distinguish between oligomerization and polymerization processes, suggesting that they have distinct physical properties 4 . At first, we describe polymerization equations, and oligomerization will be described in the next section. Polymer breakage process may play significant role as it leads to disruption and shortage of chain, but from the other side leads to increase of new polymerization seeds. Thus we modelled next processes occurring during the aggregation of Aβ peptide: nucleation, polymerization, depolymerization, breakage 1 , see Fig.S1 . We suppose also that in vivo some processes of the destruction (or resolution) of the insoluble amyloid take place 5 , which are not connected with breakage or depolymerization.
The model describes the following processes that determine the aggregation of amyloid: formation and degradation of nuclei which initiate aggregation, breakage and destruction of the fibrils.
Next, hypotheses were used for integration of aggregation and distribution models.
1) Parameters of polymerization, nucleation, breakage and oligomerization are independent in brain cells (BC) and brain interstitial fluid (BIF) compartments, but have identical rate constants which differ only between types of Aβ (40 or 42) . We introduced polymerization in BC, as the data about accumulation of intracellular Aβ exist 6 7 .
2) Destruction (efflux) of insoluble Aβ from BIF is determined mainly by microglial phagocytosis 8 , while intracellular degradation is depending on different protease activity 9 and thus rate constants of this process are different for BC and BIF.
3) Aβ can increase amyloid production by some feedback 10 11 12 mechanism, which is not described in detail in this model, but implemented in empirical functions (see supplement).
4) Amyloid synthesis in BR and OT is simplified relatively to previous distribution model and described as zero-order process.
Model includes ten differential and two algebraic equations for each type of Ab. In analogy the models published in 1 2 3 , we developed the infinite system of differential equations describing kinetics of fibril and monomer concentrations. In these papers it was assumed that non-linear process of nucleation must takes place before start of polymerization, so that several monomers should form polymerization nucleus first. The Factor of 2 appears in some rates because process of polymerization (or breakage) may occur at two sides of the existing fibril.
To decrease number of parameters and make reduction of system possible we assumed that de-polymerization constant is equal to the breakage constant. Then
-formation of fibril of i-length by binding of monomer to fibril of (i-1)-length (polymerization);
-formation of fibril of (i+1)-length by binding of monomer to fibril of ilength (polymerization); 
It can be written as
Derivation of equation for fibril concentration in terms of monomers Fm:
We assume in our model that nucleation rate is described by first order equation, i.e. nucleus contains one monomer, according to experimental data 13 , so n=1.
After reduction of similar terms and specifying compartment and amyloid form we obtain for amyloid peptide of X length (X=40 or 42) in compartment C (C is BIF or BC)
-decrease of fibril numbers due to destruction;
-formation of fibril by binding of monomer to nuclei (polymerization);
-formation of fibrils by breakage of longer fibrils (including de-polymerization);
-growth of insoluble Aβ by polymerization on fibrils;
-decrease of insoluble Aβ by de-polymerization. 
Differential equation for nuclei concentration N:
X C X C X C X C nuc Vpol Vnuc nuc Vdes dt dN _ _ − + − = (A.9) Where A.9.a) X C X c X C N des k nuc Vdes ⋅ = _ _ -destruction (degradation) of nuclei A.9.b) X C X r n X f X C N nuc k M nuc k Vnuc ⋅ − ⋅ = _ _ -formation
Description of oligomerization processes
We consider in our model that oligomerization branch is a sequence of processes separate from polymerization, and thus oligomers do not participate in accumulation of 
-formation of the hetero-tetramer.
Oligomerization model reduction
As there are no longitudinal quantitative experimental data on different oligomer forms for human, it would be difficult to calibrate the parameters accurately. To reduce the number of fitted parameters we decided to simplify the oligomerization description.
We suppose that oligomerization (dissociation of oligomers) are fast reactions with respect to other reactions (aggregation or nucleation) 15 . 
Where oligomers are expressed in terms of monomer concentration: Rates which are given in the equations are in fact apparent or effective rates which were derived because of reduction of some terms etc.
Integration of the aggregation model and distribution model. 
Model for longitudinal effects
To describe longitudinal changes in the system we supposed that rates of some processes depend on time (see main text). Time dependence of parameters was analogous according to some auxiliary function
but with special coefficients for each processes. Here Ktime, prog, tdecline are parameters of curve, t is time in years.
Next opportunities of age dependent changes were considered:
1) Decrease of degradation and transport (clearance) with age 16 17 18 dep Age tr A EFF_tr
So degradation and transcytosis parameters for each Aβ and each compartment are multiplied by this function (assumption made for simplicity).
2) Change of Aβ40 and Aβ42 synthesis in brain cells and BIF, as many mechanisms of synthesis regulation exist, and they may change with age 19 20 21 . It was shown that enzyme activity changes with age, and presenilin conformation may also 
To describe progression of disease in healthy and AD populations and in mouse we supposed that:
1) Processes of longitudinal changes (progression) are analogous in healthy subjects and AD individuals, but they hypothetically proceed with different rate and magnitude.
2) Healthy and AD subjects share physiological processes and have the same concentration of amyloid forms until the initiation of the disease progression. The parameters of different processes were assumed to change agedependently with same rate (rate of progression). Although different characteristic times of decrease should exist for age related changes of amyloid production and degradation, our model is based on the simplest hypothesis that these processes may be governed by some common process connected with aging and invariably leading to the degraded state for different processes. Each of the processes would be expected to have inter-individual variability also, but we focused on the population median as the data were at an aggregated level. This variability may be expressed as the heterogeneity observed within the AD population.
Description of feedback regulation
In many experiments and in some models feedback regulation of amyloid synthesis by amyloid itself was studied 10 11 12 . As some authors even consider this as important mechanism for the transition to the new steady state, we also introduced them into the model.
Without implying detailed mechanism of feedback we introduced it as explicit functions which describe influence of the total amyloid concentration on synthesis. We suppose some mechanism leading to increase of APP synthesis inside the cell, leading to proportional increase of release of different Aβ forms intra-and extracellularly.
Assumptions used for implementation due to lack of data 1) Parameters of regulation are the same for different forms (amyloid 40 and 42)
2) Parameters of regulation are the same for BIF and BC synthesis. As the aim was not to study the mechanisms of regulation but mainly to reflect some dynamic property of the system these simple assumptions seem reasonable. This simple Emax model is a common way to describe process assuming some receptormediated mechanism of amyloid influence, e.g., influence on Ca 2+ homeostasis through the interaction with Ca 2+ -permeable channels 27 leading to increase of amyloid production 12 .
Description of the Aβ influence on cognitive score.
To study possible influence on the disease progression we have elaborated rough simplified description of Aβ influence. We used several suggestions:
1. As the toxic species we have chosen soluble amyloid in BR (
according to in vitro data 28 29 (it has the highest toxicity, and level at which it is significant (for example, 1 nM, leading to 75% cell death in vitro), achieved earlier in AD than significant levels of insoluble Ab.
2. Toxicity is proportional (simplest model) to the level of toxic species.
3. Toxicity leads to degeneration (e.g., through oxidative stress) in but not to cell death in the model, as we suppose more auspicious conditions in vivo than in vitro (existence of some protective mechanisms which make amyloid action less pronounced). There are no irreversible changes, thus decrease of toxicity leads to increase of cognitive function. In this case we may call all scenarios as "most optimistic".
4. Value of Adas-cog for healthy subjects is about 8 30 , and the progression curve obtained during three years of observation for AD subjects (for populations with average age of 75) can be extrapolated to 80 years to yield approximate value of about 35. We have chosen parameters empirically to achieve next conditions:
gradual change of Adas-cog score from 8 to approximately 35 30 31 , score of 20 at 75 years, approximate rate of progression of 2 points/year.
5. Amyloid has a protective role on neurons and memory, according to the data from in vitro 32 and in vivo 33 studies, so we tested hypothesis that its substantial decrease leads to loss of function.
Let's suppose that level of cognition depends on the quantity of the non-degenerated neurons and on the level of their functionality ~• (B.17)
Where N is the quantity of neurons and fsol is their functional ability which may decrease with depletion of Aβ in BIF. Non-degenerated neurons are calculated through the initial quantity of neurons and portion of neurons degenerated due to Aβ toxicity.
Where ( 42 ) is unitless function of Ab. Let's suppose that change of Adas_cog score is proportional to change of cognition
ℎ is functional ability of neurons in healthy state which is equal to 1. Thus The quality of description of the data is presented in the Supplement D.
First group of hypotheses is not taking into account physiological need for the Ab, i.e.
we take fsol=1 at any values of 42 . For all hypotheses initial Adas_cog is taken to be 8. Combinatorial hypotheses are not considered in these cases, as we suppose the results analogous to some other hypotheses.
Description of human PET data
For validation of the model we collected different PET data and compared quantities DVR (distribution volume ratio) and SUVR (standardized uptake volume ration) with predictions of the model. 
Translation between human and mouse
Distribution model was constructed on wild type mouse and then scaled for human. To describe Aβ accumulation in Tg2576 mouse we have made several assumptions 1) Distribution model was constructed on wild type mouse and then scaled for human, and we suppose that Tg2576 mouse does not differ from WT mouse in distribution parameters, so scaling for is already contained in the model 2) Parameters of amyloid polymerization, oligomerization and fibril breakage presumably do not depend on the species.
3) Release of amyloid in BIF, BC and OT differs between human and TG2576
mouse, but we supposed that proportion of Aβ40 and Aβ42 remains the same.
4) Feedback effects on Aβ synthesis depend on the cell properties, should not be scaled and presumably are the same as for humans.
5) Nucleation and destruction processes depend on the properties of the organism, and should be scaled.
6) Swedish mutation, carried by Tg2576 mouse, cause mainly increase of amyloid secretion 36 , so we did not consider difference in peptide aggregation properties. Where BWm -mouse weight (25 g) and n is allometric exponent (0.85 for brain).
In mouse much higher relative increase of Aβ40 insoluble can be seen (unlike in human data). Thus we had to suppose another additional mechanism for longitudinal change of parameters -increase of Aβ40 polymerization:
Supplement C. Model calibration Assumptions to reduce number of parameters
To decrease the number of fitted parameters we made some assumptions about them or fixed their values.
Parameters for the feedback regulation were not fitted, but were assumed from the data 10 . It can be seen from the data 10 that saturation is not achieved at 1 µM. We assumed that Kef is 8 µM, and maximal effect is about 3.
1) Insoluble forms of amyloid 40 and amyloid 42 are destructed with the same rate constant in BC:
Analogous relationship was written for destruction in BIF
2) Reactions of nucleation and reverse nucleation are linear, and we suppose that it would be impossible to fit both forward and reverse rate given only the long time scale data. Thus rates for the reverse reactions (for amyloid 40 and amyloid 42) were fixed, and only parameters for forward reactions were fitted.
These assumptions were checked by fitting and did not lead to increase of objective function value (OFV, see below) after optimization.
These relationship in fact does not mean that these rates are equal in reality, it just means that these parameters are not identifiable under given set of data and are interdependent with some other parameters (for example, parameters for amyloid synthesis).
During the fitting we observed that OFV is not sensitive to parameter
_ BC des k
, and it was fixed to value 1e4.
Any additional assumptions lead to increase of OFV and thus minimal number of parameters for fitting remained equal to 21. Parameter summary is given in the Table   S3 .
Calibration algorithm
To select the values of the parameters we used the algorithm of fitting based on Hook-Jeeves method implemented in the DBSolve Optimum package 37 . As a criterion of fitness, the following function was used:
Here, n is the total number of experimental points, is the experimentally measured value of the variable, � is the value of the variable or reaction rate calculated based on the model at a point corresponding to the experimental ones. As fitted quantities are of different orders of magnitude, weighted residuals were used for fitting. To estimate values of unknown parameters, the error of the model (F) has been minimized. As the data have huge between-subject variability for some quantities and some outliers could complicate searching of the optimum and lead to the distortion of the model behavior we decided to transform some large quantities of data and to replace them by the medians for decades during the fitting.
All the stages of model fitting and validation are given in the Table 1 of the main text.
Multiple data about amyloid release and clearance exist, including human SILK data 38 39 , and they have been used during construction of the distribution model [Distrib_paper] . The distribution model parameters were taken from the stage F0 [Paper distribution], except for amyloid release rates. Release rates should be refitted for the integrated model simultaneously with other new parameters, as aggregation was not described during the distribution model development and its contribution to the total amyloid was not taken into account.For simplification we replaced description of gamma secretase functioning by zero order production in corresponding compartments.
It seems reasonable as parameters of gamma secretase would be unidentifiable on the longitudinal data set used for model fitting. Sporadic AD cases provide data only for patient ages higher than 70 years and thus there was no data on Aβ forms for patients younger than 60 years. The main aim is to describe transition from normal state to disease and thus we combined data from healthy individuals before 60 years and data for AD, according to hypotheses of age dependent changes (See above)
Parameters of the release, aggregation and longitudinal sub-models were fitted to the postmortem data for soluble and insoluble forms in brain, CSF and plasma Aβ concentration simultaneously using integrated model (See Table 1 of the main text).
Also data for in vitro aggregation kinetics exist, we supposed that these conditions poorly reconstitute in vivo situation, e.g. existence of specific polymerization nuclei (see derivation of equations), so aggregation model parameters were fitted using in vivo data.The mapping of parameter fitting stages across datasets from different species is given in Table S1 of the Supplement.
At the first stage of model fitting (F1, Table 1 of the main text) we estimated all of the parameters using this combined dataset, and some additional CSF data were used for verification. At the second stage (F2) we fitted data for healthy individuals using only different combinations of parameters of longitudinal changes in, see Supplement Table S2 for hypothesis description.
Confidence intervals for the release, aggregation and longitudinal model parameters were obtained by calculating the hessian of the fitted parameters and simulating from multivariate log-normal distribution. Simulations on 4800 samples from parameter distribution were used to calculate longitudinal confidence bands.
Confidence intervals and confidence bands for predictions were calculated using R scripts.
Fitting to the AD subjects data
Results of the fitting of the AD subjects are given in the main text and on the Figs S5-S6. Unlike Aβ42 data, Aβ40 data for AD are less extensively presented in literature, and most of sources agree that there is no change of CSF Aβ40 level in AD subjects. So during model calibration we restricted dataset to several points demonstrating clearly level of Aβ40. We can claim that model satisfactorily describes range of Aβ40 measured in AD and in healthy subjects (some of data are already aggregated as curves from LS analysis of individual points), given huge variability of the data points, although it can be seen that for Aβ40 some underestimation exists for CSF before 60 years. Aβ40 does not demonstrate decrease unlike Aβ42, probably because it less actively participates in aggregation.
During the fitting we found that time dependence of objective function value ( ( ), formula C.3) is not sensitive to parameter of Aβ40 synthesis in BIF temporal increase. Thus we set its value to zero.
Parameter of amyloid release, when normalized to volume, appeared to be close to brain amyloid synthesis. Still, plasma amyloid does not contribute significantly to the brain concentrations, corresponding to the fact that diagnosis does not determine plasma amyloid concentration 40 . Actually the mechanisms of amyloid production contribution to plasma concentration (formation in different tissues and blood cells) are out of scope of this analysis, and more accurate determination of amyloid release in OT requires more data.
Healthy subject model: hypothesis testing
Assumptions about minimal differences between healthy subjects (HS) and AD subjects were formulated. . We tried to describe HS data by minimal number of parameters, so we tried to fit 12 minimal sets of parameters.
For appropriate choice of the minimal model we divided dataset for healthy subjects into two parts -one part (training set, data for soluble and insoluble amyloid in the brain) have been used for fitting of different sets of parameters. CSF data (test set) was used for validation only.
Model statistics for different variants of fitting are given in Table S2 together Model statistics for different variants of fitting are given in Table S2 of the supplement together with results of the external model verification by the data in CSF.
Analysis of different hypotheses according to the goodness of fit, AIC and verification on independent dataset allowed to conclude that different variants of models provide similar fitting results and similar dynamic behavior.
As it was discussed in the main text, the main qualitative difference between healthy and AD subjects is decrease of Aβ concentration in BIF. Dynamics of Aβ42 is shown on the figure S6 for different types of the hypotheses from Table S2 . It can be seen that prediction about absence of Aβ decrease below physiological level in healthy subjects is robust across the different hypotheses except for the first one (H1).
Fitting to the mouse data
Parameters of the amyloid distribution and degradation processes were fitted to mouse data previously during the construction of the distribution model (Table 2) Summary of parameters fitted for mouse and Tg2576 are given in Table S3 .
Supplement D. Simulations of treatment regimens.

Simulation design
For the treatment simulations corresponding parameter of target process (release rate constant or destruction rate constant) was multiplied on the function of the drug effect
EFFdr.
For the release inhibition with switch regime (CR)
Release inhibition with PR (progressive regimen, see main text, Methods sction)
For the simulation of destruction activation during CR
For the destruction with PR
Two ages were chosen: 6 months, when there are no plaques observed and 15 months for established plaques. Maximal inhibiting levels were taken the same as for human (80% production inhibition and 600% destruction activation).
Additionally we made simulations for increase of Aβ degradation in plasma Table S2 ). Table 2 . Only results for hypotheses with ratio Rel <1 are given. 
